VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

SNPs predict sunitinib outcome in mRCC

Research has confirmed that single nucleotide polymorphisms in genes related to the processing of sunitinib influence the outcome of treatment for metastatic renal cell carcinoma.

29 May 2015

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests.

29 May 2015

Study could offer new way to treat, prevent diabetes-associated blindness

Reporting on their study with lab-grown human cells, researchers at The Johns Hopkins University and the University of Maryland say that blocking a second blood vessel growth protein, along with one that is already well-known, could offer a new way to treat and prevent a blinding eye disease caused by diabetes.

26 May 2015

Anti-VEGF therapy benefits in wet AMD not sustained

Real-world experience of anti-vascular endothelial growth factor therapy for patients with wet age-related macular degeneration suggests that initial improvements in visual acuity are not maintained over time.

20 May 2015

No added benefit with pazopanib over ranibizumab for neovascular AMD

Pazopanib eye drops do not enhance visual outcomes in patients with neovascular age-related macular degeneration beyond those achieved with ranibizumab alone, study findings indicate.

19 May 2015

Risk factors predict geographic atrophy after anti-VEGF treatment of RAP

Researchers have found three factors that could identify which patients with retinal angiomatous proliferation receiving anti-vascular endothelial growth factor treatment are likely to develop geographic atrophy.

19 May 2015

U.K Ophthalmologists lead in treatment of wet AMD patients with Oraya therapy across europe

Oraya Therapy was introduced first in the U.K., followed by Switzerland and Germany. The therapy is intended as a one-time, non-invasive treatment that maintains vision with fewer anti-vascular endothelial growth factor (anti-VEGF) injections into the eye...

19 May 2015

Trained nurses administer AMD treatments as safely and effectively as doctors

Nurses trained to deliver eye injections for patients with the wet form of age-related macular degeneration (AMD) administered the treatments as safely and effectively as doctors, according to a new study. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Denver, Colo.

6 May 2015

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

The European Commission has licensed Avastin in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. Until now, the treatment has been available ahead of licence to eligible patients in England via individual requests to the Cancer Drugs Fund (CDF).

28 Apr 2015

TSRI study provides new insight into preventing diseases that cause vision loss in adults

A new study from scientists at The Scripps Research Institute shows that nerve cells and blood vessels in the eye constantly "talk" to each other to maintain healthy blood flow and prevent disease.

28 Apr 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

Blocking Slit2 protein prevents blood vessel development that causes vasoproliferative ocular diseases

Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. A team of Inserm researchers at the Vision Institute (Inserm/CNRS/Pierre and Marie Curie University), in association with a team from the Yale Cardiovascular Research Center, have demonstrated in an animal model that blocking another protein, Slit2, prevents the pathological blood vessel development that causes these diseases.

22 Apr 2015

Current challenges in tackling macular degeneration: an interview with Mark Ackermann, AMD Alliance International

There are two forms of macular degeneration: the wet form and the dry form. The dry form is less challenging as it affects a smaller number of people and the disease progression is far slower...

21 Apr 2015

Amniotic stem cells promote growth of functional blood vessels in healing hydrogels

Rice University and Texas Children's Hospital scientists are using stem cells from amniotic fluid to promote the growth of robust, functional blood vessels in healing hydrogels.

10 Apr 2015

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) and Cellular Dynamics International, Inc. (CEO: Robert J. Palay), a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that the two companies have entered into a definitive agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger.

30 Mar 2015

IMDC prognostic model valid in second-line RCC therapy

The International Metastatic Renal Cell Carcinoma Database Consortium prognostic model can be applied to metastatic renal cell carcinoma patients receiving second-line targeted treatment, according to research published in The Lancet Oncology.

25 Mar 2015

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Use of angiotensin system inhibitors is associated with significant survival benefits in metastatic renal cell carcinoma patients treated in the targeted therapy era, research findings indicate.

25 Mar 2015

Discovery may lead to new potential treatment for drug-resistant melanoma

In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.

23 Mar 2015

VEGF News and Research

Further Reading

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

SNPs predict sunitinib outcome in mRCC

Patient characteristics may guide TKI use in CML

Study could offer new way to treat, prevent diabetes-associated blindness

Anti-VEGF therapy benefits in wet AMD not sustained

No added benefit with pazopanib over ranibizumab for neovascular AMD

Risk factors predict geographic atrophy after anti-VEGF treatment of RAP

U.K Ophthalmologists lead in treatment of wet AMD patients with Oraya therapy across europe

Trained nurses administer AMD treatments as safely and effectively as doctors

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

TSRI study provides new insight into preventing diseases that cause vision loss in adults

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Blocking Slit2 protein prevents blood vessel development that causes vasoproliferative ocular diseases

Current challenges in tackling macular degeneration: an interview with Mark Ackermann, AMD Alliance International

Amniotic stem cells promote growth of functional blood vessels in healing hydrogels

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

IMDC prognostic model valid in second-line RCC therapy

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Discovery may lead to new potential treatment for drug-resistant melanoma

Latest eBooks

Industry focus eBook - The Digital Laboratory (4th edition)

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (3rd Edition)

BFEB: Advances in microplate-based assays and analysis

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation